Evelo Biosciences, Inc.
EVLO · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.98 | 0.45 | -0.18 |
| FCF Yield | -72.58% | -30.59% | -15.58% | -57.68% |
| EV / EBITDA | -1.35 | -2.68 | -4.99 | -0.85 |
| Quality | ||||
| ROIC | -201.37% | -159.81% | -126.55% | -106.62% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.79 | 0.78 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -3.68% | -32.08% | 0.84% | -42.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.11 | 0.32 | 0.69 |
| Interest Coverage | -23.22 | -31.95 | -43.57 | -82.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |